MDGL MADRIGAL PHARMACEUTICALS, INC.
FY2025 10-K
MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed its fiscal year 2025 10-K annual report with the SEC on Feb 19, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: development and commercialization of pharmaceutical therapies for liver diseases, primarily noncirrhotic MASH
- • New product: Launch and full-year commercialization of Rezdiffra in U.S. (approved Mar 2024) and market entry in Germany (Sep 2025)
Management Discussion & Analysis
- • No revenue or YoY change figures provided in the MD&A
- • No profitability or margin percentages disclosed
Risk Factors
- • Regulatory risk: accelerated approval of Rezdiffra under FDA Subpart H pathway contingent on completing MAESTRO-NASH trials for full approval
- • Geopolitical/macro risk: U.S. Medicare drug price negotiation program starting 2026 may cap prices and impose rebates on high-spend drugs like Rezdiffra
Financial SummaryXBRL
Revenue
$958M
Net Income
-$288M
Operating Margin
-31.3%
Net Margin
-30.1%
ROE
-47.8%
Total Assets
$1.3B
EPS (Diluted)
$-12.85
Operating Cash Flow
-$190M
Source: XBRL data from MADRIGAL PHARMACEUTICALS, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on MADRIGAL PHARMACEUTICALS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.